Curis Stock Price, News & Analysis

Curis, Inc. (NASDAQ: CRIS) announced that on March 31, 2023, its independent Compensation Committee approved an inducement stock option grant for 135,450 shares to a new employee. The stock options have a ten-year term, an exercise price equal to the stock's closing price on the grant date, and will vest over four years. The vesting schedule includes 25% after the first anniversary and an additional 6.25% every three months thereafter, contingent on continued service. This grant is part of Curis's strategy to attract and retain talent as it continues to develop innovative cancer therapies.

Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, announced participation in two upcoming virtual conferences. The Cantor Fitzgerald Future of Oncology Symposium will be held from April 3 to 5, 2023, with a panel presentation on April 5 at 12:00 PM ET. The 22nd Annual Needham Virtual Healthcare Conference is set for April 17 to 20, 2023, featuring Curis on April 20 at 2:15 PM ET. Curis is recognized for its collaborations in immuno-oncology and precision oncology, with ongoing trials for its candidate emavusertib and commercial partnerships for Erivedge®.

Curis, Inc. (NASDAQ: CRIS) has successfully completed enrollment of 9 additional patients in its TakeAim Leukemia study ahead of schedule, addressing the FDA's requirements to resolve a partial clinical hold. Data from these patients is anticipated in Q2 2023, with discussions planned with the FDA for Q3 regarding the recommended Phase 2 dose for emavusertib, an IRAK-4 inhibitor. Financially, Curis reported a net loss of $56.7 million for 2022, with revenues slightly down to $10.2 million compared to the prior year. As of December 31, 2022, the company holds $85.6 million in cash, expected to fund operations into 2025.

Curis, Inc. (NASDAQ: CRIS) has announced the rescheduling of its fourth quarter business update and investor conference call from March 9, 2023, to March 13, 2023. The update will be released at 8:00 a.m. ET, followed by the conference call at 8:30 a.m. ET. To access the call, investors can dial (888)-346-6389 or (412)-317-5252 for international calls, or join via the Curis website. The company focuses on innovative cancer therapeutics, collaborating with partners like Aurigene and Genentech, currently testing drug candidates in various trials, including a Phase 1/2 trial for its IRAK4 inhibitor, emavusertib.

Curis, Inc. (NASDAQ: CRIS) announces it will release its fourth quarter 2022 financial results on March 9, 2023, following the close of U.S. markets. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results. Curis focuses on developing innovative cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech. Notably, the FDA has placed a partial clinical hold on Curis's TakeAim Leukemia trial, affecting patient enrollment for some phases. For more details, visit Curis's website.

Curis announced positive updates from the Phase 1a study of emavusertib (CA-4948) in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (hrMDS). In patients with FLT3 mutations, a 29% complete remission (CR) rate was noted, while those with spliceosome mutations saw a CR/CRh rate of 22%. Additionally, an overall response rate (ORR) of 45% was recorded in hrMDS patients. Emavusertib is also being evaluated in combination with venetoclax. The company plans to discuss a recommended Phase 2 dose with the FDA by mid-2023.

Curis, Inc. (NASDAQ: CRIS) will host a webcast on December 12, 2022, at 10:00 a.m. ET, to discuss new data from the TakeAim Leukemia trial involving emavusertib, presented at the 64th American Society of Hematology Annual Meeting. This session will include results from 28 additional evaluable AML/MDS patients, focusing on those treated with emavusertib as monotherapy and in combination with venetoclax. The call will feature leadership presentations and a Q&A session.